NAMPT and Waldenstrom macroglobulinemia: Furthermore, based on the data supporting crosstalk between oncogenic signaling and NAMPT, co-targeting NAMPT along with other signaling pathway molecules, as has been described with the BTK inhibitor ibrutinib in Waldenstrom macroglobulinemia cells, could be a promising therapeutic strategy (128).